➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Merck
Moodys
Dow
Boehringer Ingelheim

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

AUGMENTIN XR Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Augmentin Xr, and when can generic versions of Augmentin Xr launch?

Augmentin Xr is a drug marketed by Neopharma and is included in one NDA.

The generic ingredient in AUGMENTIN XR is amoxicillin; clavulanate potassium. There are forty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the amoxicillin; clavulanate potassium profile page.

Drug patent expirations by year for AUGMENTIN XR
Drug Prices for AUGMENTIN XR

See drug prices for AUGMENTIN XR

Recent Clinical Trials for AUGMENTIN XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Iqvia Pty LtdPhase 4
Birmingham Women's and Children's NHS Foundation TrustN/A
Tommy'sN/A

See all AUGMENTIN XR clinical trials

Paragraph IV (Patent) Challenges for AUGMENTIN XR
Tradename Dosage Ingredient NDA Submissiondate
AUGMENTIN XR TABLET, EXTENDED RELEASE;ORAL amoxicillin; clavulanate potassium 050785 2009-01-21

US Patents and Regulatory Information for AUGMENTIN XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AUGMENTIN XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002   Get Started Free   Get Started Free
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002   Get Started Free   Get Started Free
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002   Get Started Free   Get Started Free
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002   Get Started Free   Get Started Free
Neopharma AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.